In Case You Missed It: 
Health Affairs Blog by CMS Administrator 
Seema Verma - CMS’s Proposed Rule On 
Value-Based Purchasing For Prescription Drugs: 
New Tools For Negotiating Prices For 
The Next Generation of Therapies

Medicaid.gov sent this bulletin at 06/18/2020 11:44 AM EDT


Contact: CMS Media Relations
(202) 690-6145 | CMS Media Inquiries

CMS’s Proposed Rule On Value-Based Purchasing 
For Prescription Drugs: New Tools For Negotiating Prices 
For The Next Generation of Therapies
The Trump Administration has delivered significant policy advancements 

to lower the price of drugs and spur greater competition and innovation 
in the American health care system. As a result of actions by the Centers 
for Medicare and Medicaid Services (CMS), the average basic premium for 
Medicare Part D prescription drug plans was projected 
to decline 13.5 percent since 2017, to the lowest level in seven years, 
saving beneficiaries about $1.9 billion in premium costs over that time. 
Most recently, in March, CMS announced the Senior Savings Model, where 
participating enhanced Part D prescription drug plans across the country 
will provide Medicare beneficiaries access to a broad set of insulins at a 
maximum $35 copay for a month’s supply, saving beneficiaries on 
average 66 percent per year.

Today, we are announcing another significant step in this fight through 
a proposed overhaul of Medicaid regulations that have long inhibited 
payment innovation among prescription drugs across the entire system. 



To read the full Health Affairs blog, go to:

https://www.healthaffairs.org/do/10.1377/hblog20200617.728496/full/